jRCT2031230602进行中（未招募）不适用
A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint or the main data analysis or has been stopped prematurely.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 10age old over 至 No limit（—）
- 性别
- All
入选标准
- •Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving regorafenib as study treatment.
- •Participant is currently benefiting from treatment with regorafenib monotherapy. All participants must meet criteria to initiate a subsequent cycleof therapy, as determined by the guidelines of the feeder protocol.
- •Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and notrequiring further treatment interruption by the investigator.
排除标准
- •Ineligibility, for medical reasons, to start the subsequent cycle in the respective feeder study.
- •Participants with a beta-human chorionic gonadotropin (hCG) test result consistent with pregnancy.
- •Participants are using one or more of the prohibited medications listed in the respective feeder study protocol.
- •Participant has been previously permanently discontinued from regorafenib treatment.
研究者
相似试验
已完成
2 期
Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE)Colorectal cancerJPRN-UMIN000011294REVERCE study group180
已完成
2 期
The REPEAT trial: Regorafenib in combination with Paclitaxel in advanced oesophagogastric carcinoma, a phase 1b studyoesophageal canceroesophagogastric cancer10017991NL-OMON47541Academisch Medisch Centrum48
进行中（未招募）
1 期
Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenibMedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular carcinomaEUCTR2019-003108-10-ESFundació Clinic per a la Recerca Biomèdica60
进行中（未招募）
1 期
_Patients aged =18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.EUCTR2018-002374-46-FRICANCER89
进行中（未招募）
1 期
Regorafenib as a single agent for treatment of patients with metastatic colorectal cancer (MCRC) who are not candidates for polychemotherapyEUCTR2013-000236-94-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)